Within the proton experimental and clinical research facility the clinical gantry is used for patient studies since December 2014. Aims of the clinical trials are the reduction of the toxicity of proton therapy. In a second step also dose escalation trials for high-risk patients are intended. The trial protocols always consider translational aspects to evaluate biological mechanisms and biomarkers. Furthermore, preclinical (translational) studies intend to characterize the impact of proton radiotherapy to advance the biological treatment planning for particle therapy.
The RadPlanBio-platform (RadiationDosePlan-Image / Biomarker-Outcome-platform) is hosted by the DKTK partner sites Dresden and Heidelberg. It represents a powerful IT-infrastructure for multicentric, clinical trials as well as preclinical studies adapted for the specific needs of translational research in radiation oncology. The aim of this platform is to allow multicentric data sampling, analysis and quality assurance in radiation oncology including clinical dose-space-time resoluted analyses of radiotherapy results. All local clinical and translational studies as well as multicentric trials administrated by Dresden are carried out with the help of the RadPlanBio platform.
Biological Individualization of Radiotherapy
In the topic Biological Individualization of Radiotherapy preclinical as well as clinical parameters are investigated, which may predict the efficacy of radio(chemo)therapy. These parameters are then further developed and evaluated for the stratification of patients for certain therapy options. Furthermore, strategies for intervention against such resistance factors are investigated. All studies include imaging parameters as well as molecular markers and parameters of the tumor micromilieu.